Original research
par
Oviedo-Joekes, Eugenia et al
Date de publication
2019
Géographie
Canada
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Oui
Évalué par des pairs
Yes
L’objectif
Describes a 3-day induction protocol for injectable hydromorphone (HDM) and diacetylmorphine (DAM) used in 3 Canadian studies and examine rates of opioid-related overdose and somnolence during this induction phase.
Constatations/points à retenir
With data from 3 Canadian studies, encompassing a total of 2993 induction injections, there were only 5 related opioid overdoses that required naloxone (4 with DAM, 1 with HDM). As expected, the rate per injection day was higher for adverse events and severe adverse events during induction compared to after induction. However, all overdose events were safely treated onsite and there were no deaths or other lasting sequelae of these events. These data confirm the overall safety of iOAT during both induction and later treatment.
La conception ou méthodologie de recherche
Data from 2 clinical trials and one cohort study
Mots clés
Clinical guidance
Evidence base
Harm reduction
Safer supply
About prescribers
Outcomes
Substitution/OAT
Injecting drugs
